143 related articles for article (PubMed ID: 27160228)
1. Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.
Ravi V; Sanford EM; Wang WL; Ross JS; Ramesh N; Futreal A; Patel S; Stephens PJ; Miller VA; Ali SM
J Natl Compr Canc Netw; 2016 May; 14(5):499-502. PubMed ID: 27160228
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
Ogata D; Yanagisawa H; Suzuki K; Oashi K; Yamazaki N; Tsuchida T
Med Oncol; 2016 Oct; 33(10):116. PubMed ID: 27613162
[TBL] [Abstract][Full Text] [Related]
3. Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.
Maitland ML; Xu CF; Cheng YC; Kistner-Griffin E; Ryan KA; Karrison TG; Das S; Torgerson D; Gamazon ER; Thomeas V; Levine MR; Wilson PA; Bing N; Liu Y; Cardon LR; Pandite LN; O'Connell JR; Cox NJ; Mitchell BD; Ratain MJ; Shuldiner AR
Clin Cancer Res; 2015 Jan; 21(2):365-72. PubMed ID: 25411163
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Kitamura S; Yanagi T; Inamura Y; Hata H; Imafuku K; Yoshino K; Shimizu H
J Dermatol; 2017 Jan; 44(1):64-67. PubMed ID: 27569550
[TBL] [Abstract][Full Text] [Related]
5. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
Miura H; Shirai H
Clin Exp Dermatol; 2015 Jul; 40(5):575-7. PubMed ID: 25753734
[No Abstract] [Full Text] [Related]
6. Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
Messaritakis I; Politaki E; Plataki M; Karavassilis V; Kentepozidis N; Koinis F; Samantas E; Georgoulias V; Kotsakis A
Lung Cancer; 2017 Feb; 104():16-23. PubMed ID: 28212995
[TBL] [Abstract][Full Text] [Related]
7. A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
Oashi K; Shibata T; Namikawa K; Takahashi A; Yokota K; Nakano E; Teramoto Y; Tsutsumida A; Maeda T; Yamazaki N;
BMC Cancer; 2020 Jul; 20(1):652. PubMed ID: 32660439
[TBL] [Abstract][Full Text] [Related]
8. Angiosarcoma of the scalp successfully treated with pazopanib.
Tomita H; Koike Y; Asai M; Ogawa F; Abe K; Tanioka M; Utani A
J Am Acad Dermatol; 2014 Jan; 70(1):e19-21. PubMed ID: 24176520
[No Abstract] [Full Text] [Related]
9. Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma.
Fujita M; Endo Y; Fujisawa A; Tanioka M; Kabashima K; Miyachi Y
Eur J Dermatol; 2014; 24(2):267-8. PubMed ID: 24682601
[No Abstract] [Full Text] [Related]
10. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma.
Kitamura S; Hata H; Imafuku K; Haga N; Homma E; Shimizu H
Clin Exp Dermatol; 2015 Dec; 40(8):931-3. PubMed ID: 25817046
[No Abstract] [Full Text] [Related]
12. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
[TBL] [Abstract][Full Text] [Related]
13. OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.
Thiebaud JA; Ravi V; Litwin S; Schuetze SM; Movva S; Agulnik M; Kraft AS; Tetzlaff ED; Somaiah N; von Mehren M
Cancer; 2022 Oct; 128(19):3516-3522. PubMed ID: 35942596
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
[TBL] [Abstract][Full Text] [Related]
16. Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report.
Yang L; Liu L; Han B; Han W; Zhao M
BMC Cancer; 2018 May; 18(1):618. PubMed ID: 29855279
[TBL] [Abstract][Full Text] [Related]
17. An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial).
Mehta CR; Liu L; Theuer C
Ann Oncol; 2019 Jan; 30(1):103-108. PubMed ID: 30357394
[TBL] [Abstract][Full Text] [Related]
18. Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib.
Silva E; Gatalica Z; Vranic S; Basu G; Reddy SK; Voss A
Breast J; 2015; 21(2):205-7. PubMed ID: 25639617
[No Abstract] [Full Text] [Related]
19. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
[TBL] [Abstract][Full Text] [Related]
20. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
Hamberg P; Verweij J; Sleijfer S
Oncologist; 2010; 15(6):539-47. PubMed ID: 20511320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
